Changes to This Summary (11/21/2011)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Stage IIIB, Inoperable IIIC, IV, Recurrent, and Metastatic Breast Cancer

Added text to state that in November 2011, based on the consistent finding that bevacizumab only modestly improved progression-free survival but not overall survival, and given bevacizumab's considerable toxicity profile, the Food and Drug Administration revoked approval of bevacizumab for the treatment of metastatic breast cancer.